Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate (NYSE: CLVT) has published a white paper analyzing the pharmaceutical industry's growth potential in Latin America. The report, titled 'How is Latin America Growing?', highlights that the region's pharmaceutical market, valued at $98 billion, is projected to grow by 10.1% between 2021 and 2025.
The study emphasizes key areas for development including strategic partnerships, local API production, and regulatory modernization. Insights were gathered from discussions at the 2023 Summit LATAM in Barcelona and 2024 Summit LATAM at CPhI Milan, focusing on collaboration between industry stakeholders, government agencies, and academia.
The report outlines critical findings including: the need for transparency in partnerships, potential of local API production to reduce import dependence, AI's role in modernizing regulatory processes, and importance of consistent policies for investment and innovation.
Clarivate (NYSE: CLVT) reported Q4 2024 results with total revenue of $663.0 million, down 3.0% from Q4 2023, with organic revenues declining 0.7%. The company posted a Q4 net loss of $191.8 million ($0.27 per share), improving from a loss of $843.9 million in Q4 2023.
For full-year 2024, revenue was $2.56 billion, down 2.7% from 2023, with organic revenues decreasing 1.4%. The company generated $357.5 million in free cash flow and executed $200 million in share repurchases and $198.1 million in debt pre-payment. The board authorized a new $500 million share repurchase program for 2025-2026.
Looking ahead to 2025, Clarivate expects revenues between $2.28B-$2.40B, with recurring organic revenue growth between -1.0% to 1.0%. The company has initiated a strategic review, including potential divestitures, and plans to discontinue certain low-margin transactional products in 2025-2026.
Clarivate (NYSE:CLVT) has announced a new subscription-based content access strategy for academic institutions. The initiative introduces two key solutions: ProQuest Ebooks, offering over 700,000 Ebooks across 10 disciplines, and ProQuest Digital Collections, providing access to over 160 million primary source items along with scholarly journals, videos, and audio tracks.
The new strategy aims to address libraries' evolving needs by providing affordable and broad access to academic resources. Key features include a new Ebook Central Reader app and AI-powered research assistants. The company will phase out one-time perpetual purchases of digital collections and books throughout 2025.
This transformation responds to post-pandemic shifts in how institutions purchase academic content and the growing importance of AI-powered tools in academic research, emphasizing the need for reliable, vetted content sources.
Clarivate Plc (NYSE:CLVT) has achieved notable recognition in the WTR 1000 2025, a prestigious guide identifying top trademark professionals globally. The company has been highly recommended in three key practice areas: Trademark Management, Searching and Watching, and Renewals and Recordals.
Francois Neuville, Senior Vice President of Brand and Trademark Solutions at Clarivate, emphasized the importance of data-driven strategies in today's evolving brand landscape. He highlighted Clarivate's exceptional data quality and expertise in providing solutions throughout the trademark lifecycle, particularly noting their use of artificial intelligence and tech-enabled services to enhance decision-making efficiency.
The WTR 1000, celebrating its 15th year, conducts thorough qualitative research to identify leading professionals and firms based on expertise, market presence, and work sophistication. Recognition is granted based on positive feedback from knowledgeable market sources.
Clarivate (NYSE: CLVT) has been selected by the National and University Library in Zagreb (NSK) to provide its unified library services and discovery platform. The implementation includes Ex Libris Alma and Ex Libris Primo solutions, which will serve as a modern, unified library system across Croatia's academic and research institutions.
The cloud-based subscription service will be implemented in nine universities and 82 academic and research libraries throughout Croatia. This strategic project, part of the e-Universities initiative, is financed through the National Recovery and Resilience Plan 2021-2026. The implementation aims to streamline existing infrastructure of multiple library systems and data formats, while promoting Croatia's cultural and scientific heritage.
Clarivate (NYSE:CLVT) has published a new e-book analyzing breakthroughs in the pulsed field ablation (PFA) market for atrial fibrillation treatment. PFA technology uses high-voltage microsecond electrical pulses instead of thermal energy, offering safer and more effective procedures compared to traditional methods.
The report highlights significant market growth projections, with PFA expected to grow from $300 million (5% market share) in 2023 to $8 billion (70% market share) by 2028. Key developments include Johnson & Johnson's VARIPULSE FDA approval in November, though its U.S. rollout was paused due to safety concerns. Abbott Laboratories is anticipated to receive FDA approval by mid-2026.
International markets show strong adoption, particularly in Asia Pacific, where the market is projected to exceed $1 billion in 3-5 years, with Japan alone potentially reaching $300 million by 2028.
Clarivate (NYSE:CLVT) has released a report identifying the top 50 universities driving global innovation through academic research and patent citations. The study, leveraging data from Web of Science and Derwent databases, reveals how knowledge flows between academia and industry across different regions.
Key findings show these universities are spread across eleven countries, with U.S. institutions dominating the top positions. Harvard University leads in research output volume, while MIT demonstrates exceptional research-to-innovation translation despite smaller publication numbers. The report identifies strong regional citation patterns, with Eastern Asian and European companies primarily citing local academic research, while U.S. research maintains global influence.
Notable insights include that five organizations - Roche, Johnson & Johnson, CNRS, Samsung Electronics, and Siemens - account for 51% of citations from top innovations to academic research. The United Kingdom shows diverse international influence, often bridging regional research gaps. The report aims to help stakeholders make informed decisions about research partnerships, knowledge transfer strategies, and innovation investments.
The British Library has selected Clarivate (NYSE:CLVT) to provide its library services and discovery platforms, implementing Alma, Primo VE, and Rapido solutions. This decision builds upon a 20-year partnership and aims to create a more cohesive, streamlined, and secure experience.
The British Library, one of the world's largest libraries with a collection of 170 million items, will become the 43rd National and State library globally to adopt Alma. The implementation will unify platform operations, improve user experience, and enhance future services. The Rapido system will be used to streamline interlibrary loan processes, supporting resource sharing within the academic and research community.
Clarivate Plc (NYSE: CLVT) has announced it will release its fourth quarter and full year 2024 financial results before market opening on Wednesday, February 19, 2025. The company will make the press release and earnings supplement with financial information available on their investor website. Following the release, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.
BioWorld, published by Clarivate (NYSE:CLVT), has released its comprehensive 2024 Year in Review series analyzing key developments in biopharma, medtech, and scientific innovation. The report highlights significant therapeutic breakthroughs in psychiatry, oncology, women's health, and infectious diseases.
Key findings include the industry's resilience despite challenges, with biopharma financing and deal values rebounding amid over 18,000 job losses. Notable developments include GLP-1 receptor agonists' expansion into new therapeutic areas, significant progress in AI-driven medtech in APAC, and breakthrough cancer research data from trials like Checkmate-067 and Keynote-006.
The report also covers important regulatory changes, including the end of the Chevron doctrine affecting agency authority, and Medicare coverage challenges for emerging technologies. European biotech funding showed improvement in 2024, particularly in antibody-drug conjugates (ADCs) and CNS treatments.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
